Screener
PTC Therapeutics PTCT Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:32 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001070081-26-000012
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 3,049,569 | 3,104,080 |
| Stockholders’ deficit: | ||
| Common stock, $0.001 par value. Authorized 250,000,000 shares; issued and outstanding 82,882,024 shares at March 31, 2026. Authorized 250,000,000 shares; issued and outstanding 81,474,366 shares at December 31, 2025. | 81 | 80 |
| Additional paid-in capital | 2,778,026 | 2,748,335 |
| Accumulated other comprehensive income | 8,466 | 10,501 |
| Accumulated deficit | (2,967,038) | (2,964,229) |
| Total stockholders’ deficit | (180,465) | (205,313) |
| Total liabilities and stockholders’ deficit | $2,869,104 | $2,898,767 |
Item 1. Financial Statements (unaudited)
FAQ
- What is PTC Therapeutics's total equity?
- PTC Therapeutics (PTCT) reported total equity of -$180.47M in Q1 2026.
- How has PTC Therapeutics's total equity changed year-over-year?
- PTC Therapeutics's total equity increased by 2.9% year-over-year, from -$185.76M to -$180.47M.
- What is the long-term trend for PTC Therapeutics's total equity?
- Over 5 years (2020 to 2025), PTC Therapeutics's total equity has grown at a -15.7% compound annual growth rate (CAGR), from $481.98M to -$205.31M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about PTC Therapeutics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude